Sign in
CompletedPhase 2

A24110He in a placebo-controlled trial evaluating safety in subjects with elevated plasma triglycerides

Key facts

Who runs it
Lipigon Pharmaceuticals AB
Where
Sweden6 sites in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 2
People taking part
26 people enrolled
Started
27 Feb 2024
Ended
8 Jan 2026
Type of study
Interventional
Record updated
4 July 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 32 criteriaShow less

Who can take part

  • Provision of signed and dated, written informed consent prior to any trial specific procedures
  • Access to proper venous access as per Investigator discretion
  • Willing to comply with CTP procedures and restrictions
  • Age 18-78 years (both inclusive)
  • Women of childbearing potential (WOCBP) must have a negative pregnancy test at screening and must be using a highly effective contraceptive method. All details that need to be applied are noted in the main body text of the CTP. A woman is considered of childbearing potential if she is not surgically sterile or is less than 1 year since last menstrual period. Male subjects who are sexually active and not surgically sterile must have undergone a vasectomy or be willing to use condom or practice sexual abstinence (only allowed when this is the preferred and usual lifestyle of the subject) to prevent pregnancy and drug exposure of a partner and refrain from donating sperm from the date of dosing until 6 months after last dosing with A24110He. Their female partner of childbearing potential must use contraception methods with a failure rate of < 1% to prevent pregnancy during the trial and until 180 days after the last dose of A24110He
  • Body mass index (BMI) <38 kg/m2. Body weight ≥ 56 kg
  • History of hypertriglyceridemia prior to screening. Any lipid-lowering therapy must have been stable for at least 1 month prior to screening (visit 1) and be kept stable until randomisation (visit 4). Stable treatment is defined as unchanged in terms of dose and compound. Change of product is allowed if active substance is the same
  • Fasting TGpl levels ≥ 1.7 mmol/L at Visit 1
  • Subjects with type 2 diabetes mellitus must be on stable glucose-lowering treatment (metformin, sulfonylurea, glitazones, DPP4-inhibitors, GLP-1 agonists, SGLT2-inhibitors, repaglinide) for 3 months prior to screening (visit 1) and be kept stable until randomisation (Visit 4). Stable treatment is defined as unchanged in terms of dose and compound. Change of product is allowed if active substance is the same. The subject´s glucose control must be acceptable in terms of safety, based on the Investigator´s discretion

Who cannot take part

  • Unstable body weight, defined as more than 5% self-reported change in body weight in the period from 30 days prior to Visit 1. Intention of losing body weight within 6 months from screening
  • Participation in a clinical trial involving administration of an investigational or a marketed medicine within 3 months or five half-lives of the investigational medicine, whichever is longer, prior to Visit 4
  • Previous enrolment in the present trial, defined as having participated in any visit beyond Visit 1
  • Acute coronary syndrome < 3 months prior to Visit 1, stroke < 6 months prior to Visit 1, or symptomatic congestive heart failure
  • Any significant medical/surgical procedure or trauma within 4 weeks of the first administration of IMP, at the discretion of the Investigator
  • Any planned major surgery within the duration of the trial
  • Uncontrolled or previously unknown hypertension; SBP ≥150 mmHg, or DBP ≥95 mmHg. Antihypertensive treatment must have been stable for at least 4 weeks prior to Visit 4
  • Treatment within 6 months prior to Visit 4 with therapeutic oligonucleotides. mRNA vaccines are allowed
  • Current alcohol or drug addiction as judged by the Investigator or high-risk alcohol consumption. High-risk alcohol consumption is defined as more than 14 standard drinks for men and 9 standard drinks for women per week
  • Treatment with insulin or insulin derivatives during the last 3 months prior to Visit 4
  • Start of any medication not previously used by the subject within 2 weeks prior to Visit 1
  • > 1 hypoglycaemic episode during last month prior to Visit 1
  • Plasma donation within 1 month of Visit 1 or any blood donation or corresponding blood loss during 3 months prior to Visit 1
  • Active malignancy within the past 5 years except for in situ removal of basal cell carcinoma or non-melanoma skin cancer
  • Overt hypothyroidism, or other conditions potentially affecting plasma triglyceride levels
  • Any history of acute pancreatitis related to hypertriglyceridaemia (according to investigator judgment) or any other pancreatitis episode during the last 2 years
  • Clinically significant disease, or in any other way unsuitable for participation in this trial, which in the opinion of the Investigator might interfere with the interpretation of results and/or safety of the subject
  • Active inflammatory skin disease or contact dermatitis at Visit 1
  • ASAT, ALAT, ALP or GGT > 2.5 times upper limit of normal (ULN) or bilirubin >1.5 times ULN at Visit 1
  • S-Creatinine > 1.5 x ULN at Visit 1
  • HbA1c >70 mmol/mol at Visit 1
  • Involved in the planning and/or conduct of the trial
  • Women who are pregnant, lactating or planning to become pregnant during the trial period, or women of childbearing potential who are not using acceptable contraceptive methods

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate the safety and local tolerability of A24110He in a multiple dose trial in subjects with elevated plasma triglyceride concentrations

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A phase 2, randomised, double-blind, placebo-controlled trial to evaluate safety and local tolerability of four weekly administrations of A24110He in subjects with elevated triglyceride plasma concentrations
Record updated
4 July 2025